7,613 Shares in DENTSPLY SIRONA Inc. (XRAY) Purchased by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL acquired a new stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 7,613 shares of the medical instruments supplier’s stock, valued at approximately $494,000.

Other hedge funds have also made changes to their positions in the company. Alps Advisors Inc. lifted its stake in DENTSPLY SIRONA by 0.3% in the second quarter. Alps Advisors Inc. now owns 7,523 shares of the medical instruments supplier’s stock worth $488,000 after acquiring an additional 20 shares during the last quarter. Wetherby Asset Management Inc. lifted its stake in DENTSPLY SIRONA by 0.6% in the second quarter. Wetherby Asset Management Inc. now owns 5,004 shares of the medical instruments supplier’s stock worth $324,000 after acquiring an additional 30 shares during the last quarter. HighTower Advisors LLC lifted its stake in DENTSPLY SIRONA by 0.6% in the first quarter. HighTower Advisors LLC now owns 6,823 shares of the medical instruments supplier’s stock worth $424,000 after acquiring an additional 39 shares during the last quarter. BRYN MAWR TRUST Co lifted its stake in DENTSPLY SIRONA by 0.5% in the second quarter. BRYN MAWR TRUST Co now owns 12,064 shares of the medical instruments supplier’s stock worth $782,000 after acquiring an additional 65 shares during the last quarter. Finally, Atria Investments LLC lifted its stake in DENTSPLY SIRONA by 1.5% in the second quarter. Atria Investments LLC now owns 4,541 shares of the medical instruments supplier’s stock worth $294,000 after acquiring an additional 68 shares during the last quarter. Hedge funds and other institutional investors own 93.88% of the company’s stock.

XRAY has been the subject of a number of recent research reports. UBS AG reiterated a “neutral” rating and issued a $59.00 price target (down previously from $62.00) on shares of DENTSPLY SIRONA in a research note on Thursday, August 10th. BidaskClub downgraded shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Jefferies Group LLC decreased their price target on shares of DENTSPLY SIRONA from $72.00 to $66.00 and set a “buy” rating for the company in a research note on Wednesday, August 23rd. Cleveland Research downgraded shares of DENTSPLY SIRONA from a “buy” rating to a “neutral” rating in a research note on Thursday, October 5th. Finally, Zacks Investment Research downgraded shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Three analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $65.89.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://ledgergazette.com/2017/10/11/7613-shares-in-dentsply-sirona-inc-xray-purchased-by-tudor-investment-corp-et-al.html.

Shares of DENTSPLY SIRONA Inc. (XRAY) opened at 57.57 on Wednesday. The stock’s 50 day moving average is $57.50 and its 200 day moving average is $61.17. DENTSPLY SIRONA Inc. has a 12 month low of $52.54 and a 12 month high of $65.68. The stock’s market cap is $13.21 billion.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.65. DENTSPLY SIRONA had a negative net margin of 20.57% and a positive return on equity of 7.24%. The company had revenue of $992.70 million during the quarter, compared t

Other hedge funds have also made changes to their positions in the company. Alps Advisors Inc. lifted its stake in DENTSPLY SIRONA by 0.3% in the second quarter. Alps Advisors Inc. now owns 7,523 shares of the medical instruments supplier’s stock worth $488,000 after acquiring an additional 20 shares during the last quarter. Wetherby Asset Management Inc. lifted its stake in DENTSPLY SIRONA by 0.6% in the second quarter. Wetherby Asset Management Inc. now owns 5,004 shares of the medical instruments supplier’s stock worth $324,000 after acquiring an additional 30 shares during the last quarter. HighTower Advisors LLC lifted its stake in DENTSPLY SIRONA by 0.6% in the first quarter. HighTower Advisors LLC now owns 6,823 shares of the medical instruments supplier’s stock worth $424,000 after acquiring an additional 39 shares during the last quarter. BRYN MAWR TRUST Co lifted its stake in DENTSPLY SIRONA by 0.5% in the second quarter. BRYN MAWR TRUST Co now owns 12,064 shares of the medical instruments supplier’s stock worth $782,000 after acquiring an additional 65 shares during the last quarter. Finally, Atria Investments LLC lifted its stake in DENTSPLY SIRONA by 1.5% in the second quarter. Atria Investments LLC now owns 4,541 shares of the medical instruments supplier’s stock worth $294,000 after acquiring an additional 68 shares during the last quarter. Hedge funds and other institutional investors own 93.88% of the company’s stock.

XRAY has been the subject of a number of recent research reports. UBS AG reiterated a “neutral” rating and issued a $59.00 price target (down previously from $62.00) on shares of DENTSPLY SIRONA in a research note on Thursday, August 10th. BidaskClub downgraded shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Jefferies Group LLC decreased their price target on shares of DENTSPLY SIRONA from $72.00 to $66.00 and set a “buy” rating for the company in a research note on Wednesday, August 23rd. Cleveland Research downgraded shares of DENTSPLY SIRONA from a “buy” rating to a “neutral” rating in a research note on Thursday, October 5th. Finally, Zacks Investment Research downgraded shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Three analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $65.89.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://ledgergazette.com/2017/10/11/7613-shares-in-dentsply-sirona-inc-xray-purchased-by-tudor-investment-corp-et-al.html.

Shares of DENTSPLY SIRONA Inc. (XRAY) opened at 57.57 on Wednesday. The stock’s 50 day moving average is $57.50 and its 200 day moving average is $61.17. DENTSPLY SIRONA Inc. has a 12 month low of $52.54 and a 12 month high of $65.68. The stock’s market cap is $13.21 billion.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.65. DENTSPLY SIRONA had a negative net margin of 20.57% and a positive return on equity of 7.24%. The company had revenue of $992.70 million during the quarter, compared to the consensus estimate of $1 billion. During the same quarter last year, the company earned $0.76 earnings per share. DENTSPLY SIRONA’s revenue for the quarter was down 2.9% on a year-over-year basis. Analysts predict that DENTSPLY SIRONA Inc. will post $2.68 earnings per share for the current fiscal year.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY).

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply